Low-Dose CT-Based Method in Detecting of Subclinical Anthracycline-Induced Cardiotoxicity in Cancer Patients

Inclusion Criteria

• Ability to understand and the willingness to sign a written informed consent
• Patients with newly-diagnosed, biopsy-confirmed cancer scheduled to undergo anthracycline-based chemotherapy (minimum of 200 mg/m^2 of doxorubicin or equivalent) at University of California San Diego (UCSD) Medical Center
• Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: ** Has not undergone a hysterectomy or bilateral oophorectomy; or ** Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
• Women of child-bearing potential must have a negative pregnancy test during the screening period

Exclusion Criteria

• Prior chemotherapy with anthracycline
• Persistent tachycardia (heart rate > 90)
• LVEF < 53% or history of cardiomyopathy or decompensated heart failure
• Baseline GLS below lower limit of normal (normal range varies depending on age and gender) or inability to obtain meaningful strain data due to poor quality of echocardiographic images
• Known unrevascularized coronary artery disease, myocardial infarction within 30 days of enrollment
• Moderate or severe valvular heart disease
• Prior allergy or intolerance to iodinated contrast
• Renal failure (glomerular filtration rate [GFR] < 30, creatinine > 1.5)
• Cancer involvement of the heart